Cacti Asset Management LLC Sells 25,000 Shares of Fresenius Medical Care AG (NYSE:FMS)

Cacti Asset Management LLC reduced its holdings in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 73.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,000 shares of the company's stock after selling 25,000 shares during the quarter. Cacti Asset Management LLC's holdings in Fresenius Medical Care were worth $204,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Wulff Hansen & CO. increased its holdings in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company's stock worth $6,556,000 after acquiring an additional 325,439 shares during the period. Moran Wealth Management LLC increased its holdings in shares of Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock worth $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP raised its position in shares of Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company's stock worth $2,345,000 after buying an additional 48,554 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Fresenius Medical Care by 60.4% during the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock valued at $1,340,000 after buying an additional 23,692 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Fresenius Medical Care during the third quarter worth about $420,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on FMS. Truist Financial raised their price target on Fresenius Medical Care from $22.00 to $23.00 and gave the company a "hold" rating in a report on Monday, October 7th. Bank of America upgraded shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research report on Monday, December 2nd. Berenberg Bank began coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a "buy" rating and a $25.60 price target for the company. Finally, StockNews.com initiated coverage on shares of Fresenius Medical Care in a research report on Thursday, November 28th. They set a "strong-buy" rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $24.30.

Fresenius Medical Care Price Performance

FMS traded down $0.49 during midday trading on Thursday, hitting $22.15. The stock had a trading volume of 233,877 shares, compared to its average volume of 353,043. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $24.31. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The business has a fifty day moving average of $22.21 and a 200 day moving average of $20.64. The company has a market cap of $13.00 billion, a P/E ratio of 18.31, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.